Coeptis Therapeutics Holdings, Inc. (ticker: COEP) is an NASDAQ-listed finance services company. DredgeCap's structured extraction of COEP's SEC filings surfaces 10 active risk signals, including 6 late-filing signals, 2 delisting/deregistration signals, and 2 auditor-change signals. COEP reported $1.36M in revenue and -$11.92M for the period ending 2025-12-31, with operating cash flow of -$8.60M. Cash and equivalents stood at $5.67M (up 964.8% year-over-year). Total assets of $16.15M exceed total liabilities of $2.09M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
COEP SEC Filings
Full cached SEC EDGAR filing history for COEP, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.